|Bid||0.00 x 2200|
|Ask||0.00 x 900|
|Day's Range||6.61 - 6.88|
|52 Week Range||5.86 - 21.30|
|Beta (5Y Monthly)||-0.26|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 12, 2021 - May 17, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.60|
(NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced the acquisition of a global license to AR101 (enzastaurin), a pivotal study-ready therapeutic candidate initially targeting the treatment of vascular Ehlers-Danlos Syndrome (vEDS) from Rumpus Therapeutics (Rumpus), a privately-held biopharmaceutical company focused on the treatment of pediatric onset rare and orphan diseases. vEDS is a rare genetic disorder typically diagnosed in childhood and characterized by arterial aneurysm, dissection and rupture, bowel rupture and rupture of the gravid uterus.
ENGLEWOOD, CO / ACCESSWIRE / April 5, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced the appointment of Richard Eisenstadt as Chief Financial Officer.
Specialty pharmaceutical company Aytu BioPharma Inc agreed to divest all remaining U.S. rights to Natesto to Acerus Pharma for a total consideration of $7.5 million. This consideration is payable in 30 monthly instalments of $250,000. Aytu BioPharma’s (AYTU) Chief Executive Officer, Josh Disbrow said, “This strategic transaction is an important milestone for Aytu BioPharma as it solidifies our go-forward therapeutic focus on pediatric medicine and plan to become a leading specialty paediatrics company.” Disbrow further added, “In conjunction with finalizing and closing the merger with Neos Therapeutics, we conducted a strategic review of our legacy Rx business. Following that review, we believe focusing commercial efforts on our newly expanded portfolio of ADHD and pedriatic products provides the best opportunity to increase shareholder value.” (See Aytu BioPharma stock analysis on TipRanks) Acerus is also purchasing all Natesto inventory from Aytu and assumed Natesto product responsibilities from April 1. Aytu closed its merger with Neos Therapeutics on March 22. This transformed it into a specialty pharma company with $100 million in revenue. On March 29, Cantor Fitzgerald analyst Jennifer Kim assigned the stock a Buy rating and a price target of $11 (45% upside potential). Kim commented, Aytu has built up “a highly diversified, growing portfolio” focused on paediatrics and thinks Aytu’s opportunities for sales growth remain “underappreciated.” The other analyst covering the stock, H. C. Wainwright’s Vernon Bernardino also has a Buy rating on the stock and a price target of $24 (217.5% upside potential). The two ratings combine to a Moderate Buy consensus rating with average analyst price target of $17.50 (131.5% upside potential. Shares have dropped about 50.6% over the past year. Related News: Angi Increases Stake In MyBuilder Business By 20%; Street Remains Bullish Chart Industries Buys 5% Stake In Transform Materials, Signs MOU Renewable Energy Collaborates With Optimus Technologies On Biodiesel Delivery More recent articles from Smarter Analyst: The Pennant Group Acquires Pasco Southwest Home Health Franklin Electric Snaps Up Puronics Wingstop Rises 8.5% On Strong 1Q Preliminary Sales Standex Sells Enginetics Corporation For $11.5M In Cash